Armin R Afshar

Dr. Armin R Afshar


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2019 in Ophthalmology
Verified
Journal Article
Closed access
AAArmin R Afshar
Armin R Afshar
MPMelike Pekmezci
Melike Pekmezci
MBMichele M. Bloomer
Michele M. Bloomer
NCNicola J. Cadenas
Nicola J. Cadenas
MSMeredith Stevers
Meredith Stevers
BDBertil E. Damato
Bertil E. Damato

1 March 2019 in Translational Vision Science & Technology
Verified
Journal Article
Open access
PDF file
AAArmin R Afshar
Armin R Afshar
BDBertil E. Damato
Bertil E. Damato
JSJay M. Stewart
Jay M. Stewart
LZLydia B. Zablotska
Lydia B. Zablotska
RRRitu Roy
Ritu Roy
BBBoris C. Bastian
Boris C. Bastian
Purpose: To clinically use the UCSF500, a pancancer, next-generation sequencing assay in uveal melanoma (UM) and to correlate results with gene expression profiling (GEP) and predictive factors for metastasis. Methods: Cohort study. Tumor samples of adult UM patients were analyzed with the UCSF500 and GEP. Main outcomes were copy number changes in chromosomes 1, 3, 6, and 8 and mutations in GNAQ, GNA11, SF3B1, EIF1AX, BAP1, SRSF2, U2AF1, and PLCB4. Chromosome 3 loss (a metastasis predictor) was tested for correlation with GEP class, tumor characteristics (largest basal diameter, thickness, ciliary body involvement, and extraocular extension), and histology (presence of epithelioid cells, closed loops, and mitotic count). Results: The 62 patients had a mean age of 59 years (range, 24–89 years). Chromosome 3 loss was detected in 30 patients and was associated with larger basal tumor diameter (Wilcoxon rank sum test, P = 0.015), greater thickness (Wilcoxon rank sum test, P = 0.016) and tumor, node, metastasis stage (Fisher test, P = 0.006), epithelioid cytology (Fisher test, P < 0.001), BAP1 mutation (Fisher test, P < 0.001), and chromosome 8q gain (Fisher test, P < 0.001). Class 2 tumors were much more likely to have chromosome 3 loss than class 1 (odds ratio, 121; P < 0.001). Eleven patients developed metastatic UM, of which five died during the study. All metastatic cases had chromosome 3 loss, 8 gain, BAP1 mutation, and class 2 GEP. Five class 1 tumors had chromosome 3 loss. Conclusions: UCSF500 detects chromosomal copy number changes and missense mutations that correlate strongly with metastasis predictors, including GEP. Translational Relevance: Next-generation sequencing of UM should enhance survival prognostication.

18 February 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Alda Maria Cunha RolaAlda Maria Cunha Rola
Alda Maria Cunha Rola
ATAzzam Taktak
Azzam Taktak
AEAntonio Eleuteri
Antonio Eleuteri
HKHelen Kalirai
Helen Kalirai
HHHeinrich Heimann
Heinrich Heimann
Sarah E. CouplandSarah E. Coupland
Sarah E. Coupland
Uveal melanoma (UM) is fatal in ~50% of patients as a result of disseminated disease. This study aims to externally validate the Liverpool Uveal Melanoma Prognosticator Online V3 (LUMPO3) to determine its reliability in predicting survival after treatment for choroidal melanoma when utilizing external data from other ocular oncology centers. Anonymized data of 1836 UM patients from seven international ocular oncology centers were analyzed with LUMPO3 to predict the 10-year survival for each patient in each external dataset. The analysts were masked to the patient outcomes. Model predictions were sent to an independent statistician to evaluate LUMPO3’s performance using discrimination and calibration methods. LUMPO3’s ability to discriminate between UM patients who died of metastatic UM and those who were still alive was fair-to-good, with C-statistics ranging from 0.64 to 0.85 at year 1. The pooled estimate for all external centers was 0.72 (95% confidence interval: 0.68 to 0.75). Agreement between observed and predicted survival probabilities was generally good given differences in case mix and survival rates between different centers. Despite the differences between the international cohorts of patients with primary UM, LUMPO3 is a valuable tool for predicting all-cause mortality in this disease when using data from external centers.

8 February 2018 in Ocular Oncology and Pathology
Verified
Journal Article
Open access
PDF file
AAArmin R Afshar
Armin R Afshar
MDMichael Deiner
Michael Deiner
Grant AllenGrant Allen
Grant Allen
Bertil E. DamatoBertil E. Damato
Bertil E. Damato
Background: Ocular melanomas threaten patients with early death, visual handicap, and loss of the eye. The aims of this study were to identify aspects of care that patients with ocular melanoma considered most important and to determine whether patients felt their needs had been adequately addressed. Methods: A cross-sectional study including US ocular melanoma patients and their caregivers. An online survey of US ocular melanoma patients was designed and conducted by the Ocular Melanoma Foundation. Results: The cohort included 180 patients with uveal melanoma and 4 with conjunctival melanoma. Median follow-up was 3 years. A third of patients reported that their uveal melanoma had initially been diagnosed as a nevus. Most uveal melanomas were treated with brachytherapy. Almost 50% of patients had no genetic tumor analysis. Screening methods reported most commonly were computed tomography and liver function tests. Metastatic disease developed in 11% of patients. Few patients (13.3%) reported an offer of psychological support. Most dissatisfaction was with lack of advice on financial aspects of care and lack of psychological counseling, with women tending to express more dissatisfaction with care. Many patients complained about the way ophthalmologists delivered bad news to them. Conclusions: This patients' perspective highlights directions for research, education, and other measures to improve the care of patients with ocular melanoma in the US and elsewhere.

8 August 2018 in Ocular Oncology and Pathology
Verified
Journal Article
Closed access
LELesley Everett
Lesley Everett
Bertil E. DamatoBertil E. Damato
Bertil E. Damato
MBMichele M. Bloomer
Michele M. Bloomer
JPJames D. Palmer
James D. Palmer
AKAndrew A. Kao
Andrew A. Kao
AAArmin R Afshar
Armin R Afshar
Purpose: To report a case of metastatic cutaneous melanoma presenting with choroidal metastasis simulating primary uveal melanoma. Design: Case report. Method: Presentation of clinical, radiographic, histopathologic, and tumor genetic findings in a patient with cutaneous melanoma with choroidal metastasis. Results: A 50-year-old man with a remote history of stage 1A cutaneous melanoma presented with eye pain, peripheral vision loss, floaters, red eye, and choroidal mass that was originally diagnosed as a primary uveal melanoma at an outside institution; however, subsequent imaging and clinical evaluation demonstrated that this choroidal mass was the first manifestation of widely metastatic cutaneous melanoma (liver, pancreas, lung, bone, brain, and orbit lesions). Histopathologic analysis of the tumor after enucleation was consistent with cutaneous melanoma, and tumor genetic testing was positive for BRAF V600E mutation, confirming the choroidal lesion to be a cutaneous melanoma metastasis rather than a primary choroidal melanoma. Conclusions: Metastatic cutaneous melanoma to the orbit or globe occurs rarely. Tumor genetic testing may help differentiate metastatic cutaneous melanoma from primary uveal melanoma in cases where the diagnosis is uncertain, and can also inform therapy and prognostic counseling.

1 July 2020 in Advances in Radiation Oncology
Verified
Journal Article
Open access
KMKavita K. Mishra
Kavita K. Mishra
AAArmin R Afshar
Armin R Afshar
Juliette THARIATJuliette THARIAT
Juliette THARIAT
HSHelen A. Shih
Helen A. Shih
JSJess Scholey
Jess Scholey
Bertil E. DamatoBertil E. Damato
Bertil E. Damato
Uveal melanoma (UM) is a rare but life-threatening cancer of the eye. In light of the COVID-19 pandemic, hospitals and proton eye therapy facilities must analyze several factors to ensure appropriate treatment protocols for patients and provider teams. Practice considerations to limit COVID-19 transmission in the proton ocular treatment setting for UM are necessary. The Particle Therapy Co-Operative Group (PTCOG) is the largest international community of particle/proton therapy providers. Participating experts are/were affiliated with the member institutions of the PTCOG Ocular subcommittee with long-standing high-volume proton ocular programs. The practices reviewed in this document must be taken in conjunction with local hospital procedures, multidisciplinary recommendations, and regional/national guidelines, as each community may have its unique needs, supplies, and protocols. Importantly, as the pandemic evolves, so will the strategies and recommendations. Given the unique circumstances for UM patients, along with indications of potential ophthalmologic transmission as a result of healthcare providers working in close proximity to patients and intrinsic infectious risk from eyelashes, tears and hair, practice strategies may be adapted to reduce the risk of viral transmission. Certainly, providers and health care systems will continue to examine and provide as safe and effective care as possible for patients in the current environment.